Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo

PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.

Abstract

The rapid expansion of commercially available fermented food products raises important safety issues particularly when infant food is concerned. In many cases, the activity of the microorganisms used for fermentation as well as what will be the immunological outcome of fermented food intake is not known. In this manuscript we used complex in vitro, ex-vivo and in vivo systems to study the immunomodulatory properties of probiotic-fermented products (culture supernatant and fermented milk without live bacteria to be used in infant formula). We found in vitro and ex-vivo that fermented products of Lactobacillus paracasei CBA L74 act via the inhibition of proinflammatory cytokine release leaving anti-inflammatory cytokines either unaffected or even increased in response to Salmonella typhimurium. These activities are not dependent on the inactivated bacteria but to metabolic products released during the fermentation process. We also show that our in vitro systems are predictive of an in vivo efficacy by the fermented products. Indeed CBA L74 fermented products (both culture medium and fermented milk) could protect against colitis and against an enteric pathogen infection (Salmonella typhimurium). Hence we found that fermented products can act via the inhibition of immune cell inflammation and can protect the host from pathobionts and enteric pathogens. These results open new perspectives in infant nutrition and suggest that L. paracasei CBA L74 fermented formula can provide immune benefits to formula-fed infants, without carrying live bacteria that may be potentially dangerous to an immature infant immune system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Colitis / drug therapy
  • Colitis / microbiology
  • Colitis / prevention & control*
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism*
  • Fermentation / drug effects*
  • Humans
  • Infant
  • Infant Formula / administration & dosage
  • Infant Formula / pharmacology*
  • Inflammation Mediators / metabolism
  • Lactobacillus / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Milk / metabolism*
  • Protective Agents / administration & dosage
  • Protective Agents / pharmacology
  • Protective Agents / therapeutic use
  • Salmonella Infections, Animal / microbiology
  • Salmonella Infections, Animal / prevention & control
  • Salmonella typhimurium / drug effects*
  • Salmonella typhimurium / physiology

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • Protective Agents

Grant support

The work was supported by Heinz. The funders supplied the fermented milk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.